Reductions in levels of the Alzheimer's amyloid β peptide after oral administration of ginsenosides

FASEB Journal

Volumn 20, Issue 8, 2006, Pages

  Chen, Feng ^a   Eckman, Elizabeth A ^a   Eckman, Christopher B ^a  

^a MAYO CLINIC   (United States)

Author keywords

Ginseng; RE; Rg1; Rg3; Tg2576

Indexed keywords

AMYLOID BETA PROTEIN; GINSENOSIDE; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; GINSENOSIDE RG 3; PEPTIDE FRAGMENT; PLANT EXTRACT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; DRUG EFFECT; IN VIVO STUDY; MEDICAL RESEARCH; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; CHO CELL; CRICETULUS; FEMALE; GENETICS; GINSENG; HAMSTER; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; TRANSGENIC MOUSE;

ANIMALIA; PANAX GINSENG;

ADMINISTRATION, ORAL; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; GINSENOSIDES; HUMANS; MICE; MICE, TRANSGENIC; PANAX; PEPTIDE FRAGMENTS; PLANT EXTRACTS;

EID: 33845672995     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.05-5530fje     Document Type: Article

References (49)

1. Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., and Evans, D. A. (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60, 1119-1122
2. Hardy, J., and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356
3. Scarpini, E., Scheltens, P., and Feldman, H. (2003) Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2, 539-547
4. Dominguez, D. I., and De Strooper, B. (2002) Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. Trends Pharmacol. Sci. 23, 324-330
5. Attele, A. S., Wu, J. A., and Yuan, C. S. (1999) Ginseng pharmacology: multiple constituents and multiple actions. Biochem. Pharmacol. 58, 1685-1693
6. Barnes P. M., Powell-Griner, E., McFann, K., and Nahin, R. L. (2004) Complementary and alternative medicine use among adults: United States, 2002. In Advance Data from Vital and Health Statistics (no. 343), National Center for Health Statistics, Hyattsville, MD
7. Kaufman, D. W., Kelly, J. P., Rosenberg, L., Anderson, T. E., and Mitchell, A. A. (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. Jama 287, 337-344
8. Harnack, L. J., Rydell, S. A., and Stang, J. (2001) Prevalence of use of herbal products by adults in the Minneapolis/St. Paul, Minn., metropolitan area. Mayo Clin. Proc. 76, 688-694
9. Huang, K. C. (1999) The Pharmacology of Chinese Herbs, CRC Press, Boca Raton, FL
10. Liu, Z. Q., Luo, X. Y., Liu, G. Z., Chen, Y. P., Wang, Z. C., and Sun, Y. X. (2003) In vitro study of the relationship between the structure of ginsenoside and its antioxidative or prooxidative activity in free radical induced hemolysis of human erythrocytes. J. Agric. Food Chem. 51, 2555-2558
11. Vogler, B. K., Pittler, M. H., and Ernst, E. (1999) The efficacy of ginseng. A systematic review of randomised clinical trials. Eur. J. Clin. Pharmacol. 55, 567-575
12. D'Angelo, L., Grimaldi, R., Caravaggi, M., Marcoli, M., Perucca, E., Lecchini, S., Frigo, G. M., and Crema, A. (1986) A double-blind, placebo-controlled clinical study on the effect of a standardized ginseng extract on psychomotor performance in healthy volunteers. J. Ethnopharmacol. 16, 15-22
13. Sorensen, H., and Sonne, J. (1996) A double-masked study of the effect of ginseng on cognitive functions. Curr. Ther. Res. 57, 959-968
14. Winther, K., Ranlov, C., Rein, E., and Mehlsen, J. (1997) Russian root (Siberian ginseng) improves cognitive functions in middle-aged people, whereas Ginkgo biloba seems effective only in the elderly. J. Neurol. Sci. 150, S90
15. Garcia, R. (1988) Estudio comparativo de dos farmacos que actuan sobre el envejecimiento cerebral. Prensa Med. Argent. 75, 134-139
16. Kennedy, D. O., Scholey, A. B., and Wesnes, K. A. (2001) Dose dependent changes in cognitive performance and mood following acute administration of Ginseng to healthy young volunteers. Nutr. Neurosci. 4, 295-310
17. Kennedy, D. O., Scholey, A. B., and Wesnes, K. A. (2002) Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. Physiol. Behav. 75, 739-751
18. Kennedy, D. O., and Scholey, A. B. (2003) Ginseng: potential for the enhancement of cognitive performance and mood. Pharmacol. Biochem. Behav. 75, 687-700
19. Kennedy, D. O., Haskell, C. F., Wesnes, K. A., and Scholey, A. B. (2004) Improved cognitive performance in human volunteers following administration of guarana (Paullinia cupana) extract: comparison and interaction with Panax ginseng. Pharmacol. Biochem. Behav. 79, 401-411
20. Kennedy, D. O., Scholey, A. B., Drewery, L., Marsh, V. R., Moore, B., and Ashton, H. (2003) Electroencephalograph effects of single doses of Ginkgo biloba and Panax ginseng in healthy young volunteers. Pharmacol. Biochem. Beha.v 75, 701-709
21. Oishi, M., Mochizuki, Y., Takasu, T., Chao, E., and Nakamura, S. (1998) Effectiveness of traditional Chinese medicine in Alzheimer disease. Alzheimer Dis .Assoc. Disord. 12, 247-250
22. Polich, J., and Corey-Bloom, J. (2005) Alzheimer's disease and P300: review and evaluation of task and modality. Curr. Alzheimer Res. 2, 515-525
23. Katada, E., Sato, K., Sawaki, A., Dohi, Y., Ueda, R., and Ojika, K. (2003) Long-term effects of donepezil on P300 auditory event-related potentials in patients with Alzheimer's disease. J. Geriatr. Psychiatry Neurol. 16, 39-43
24. Katada, E., Sato, K., Ojika, K., and Ueda, R. (2004) Cognitive event-related potentials: useful clinical information in Alzheimer's disease. Curr. Alzheimer Res. 1, 63-69
25. Haugabook, S. J., Yager, D. M., Eckman, E. A., Golde, T. E., Younkin, S. G., and Eckman, C. B. (2001) High throughput screens for the identification of compounds that alter the accumulation of the Alzheimer's amyloid β peptide (Aβ). J. Neurosci. Methods 108, 171-179
26. Murphy, M. P., Uljon, S. N., Fraser, P. E., Fauq, A., Lookingbill, H. A., Findlay, K. A., Smith, T. E., Lewis, P. A., McLendon, D. C., Wang, R., and Golde, T. E. (2000) Presenilin 1 regulates pharmacologically distinct gamma-secretase activities. Implications for the role of presenilin in gamma-secretase cleavage. J. Biol. Chem. 275, 26277-26284
27. Suzuki, N., Cheung, T. T., Cai, X. D., Odaka, A., Otvos, L., Jr., Eckman, C., Golde, T. E., and Younkin, S. G. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 1336-1340
28. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice [see comments]. Science 274, 99-102
29. Irizarry, M. C., McNamara, M., Fedorchak, K., Hsiao, K., and Hyman, B. T. (1997) APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1 [see comments]. J. Neuropathol. Exp. Neurol. 56, 965-973
30. Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97-100
31. Haugabook, S. J., Le, T., Yager, D., Zenk, B., Healy, B. M., Eckman, E. A., Prada, C., Younkin, L., Murphy, P., Pinnix, I., et al. (2001) Reduction of Aβ accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin. FASEB J. 15, 16-18
32. Best, J. D., Jay, M. T., Otu, F., Ma, J., Nadin, A., Ellis, S., Lewis, H. D., Pattison, C., Reilly, M., Harrison, T., et al. (2005) Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-ox o-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. J. Pharmacol. Exp. Ther. 313, 902-908
33. Lanz, T. A., Fici, G. J., and Merchant, K. M. (2005) Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J. Pharmacol. Exp. Ther. 312, 399-406
34. Lanz, T. A., Hosley, J. D., Adams, W. J., and Merchant, K. M. (2004) Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6, 7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). J. Pharmacol. Exp. Ther. 309, 49-55
35. Roch, J. M., Masliah, E., Roch-Levecq, A. C., Sundsmo, M. P., Otero, D. A., Veinbergs, I., and Saitoh, T. (1994) Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor. Proc. Natl. Acad. Sci. U. S. A. 91, 7450-7454
36. Bour, A., Little, S., Dodart, J. C., Kelche, C., and Mathis, C. (2004) A secreted form of the beta-amyloid precursor protein (sAPP695) improves spatial recognition memory in OF1 mice. Neurobiol. Learn Mem. 81, 27-38
37. Milward, E. A., Papadopoulos, R., Fuller, S. J., Moir, R. D., Small, D., Beyreuther, K., and Masters, C. L. (1992) The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 9, 129-137
38. Mattson, M. P., Cheng, B., Culwell, A. R., Esch, F. S., Lieberburg, I., and Rydel, R. E. (1993) Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10, 243-254
39. Spinella, M. (2001) The Psychopharmacology of Herbal Medicine, The MIT Press
40. Tohda, C., Kuboyama, T., and Komatsu, K. (2005) Search for natural products related to regeneration of the neuronal network. Neurosignals 14, 34-45
41. Lian, X. Y., Zhang, Z., and Stringer, J. L. (2005) Protective effects of ginseng components in a rodent model of neurodegeneration. Ann. Neurol. 57, 642-648
42. Koo, B. S., Kim, Y. K., Park, K. S., Chung, K. H., and Kim, C. H. (2004) Attenuating effect of a traditional korean formulation, Paeng-Jo-Yeon-Nyeon- Baek-Ja-In-Hwan (PJBH), on hydrogen peroxide-induced injury in PC12 cells. Phytother. Res. 18, 488-493
43. Kim, Y. C., Kim, S. R., Markelonis, G. J., and Oh, T. H. (1998) Ginsenosides Rb1 and Rg3 protect cultured rat cortical cells from glutamate-induced neurodegeneration. J. Neurosci. Res. 53, 426-432
44. Tohda, C., Matsumoto, N., Zou, K., Meselhy, M. R., and Komatsu, K. (2004) Abeta(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, A metabolite of protopanaxadiol-type saponins. Neuropsychopharmacology 29, 860-868
45. Bao, H. Y., Zhang, J., Yeo, S. J., Myung, C. S., Kim, H. M., Kim, J. M., Park, J. H., Cho, J., and Kang, J. S. (2005) Memory enhancing and neuroprotective effects of selected ginsenosides. Arch. Pharm. Res. 28, 335-342
46. Nishijo, H., Uwano, T., Zhong, Y. M., and Ono, T. (2004) Proof of the mysterious efficacy of ginseng: basic and clinical trials: effects of red ginseng on learning and memory deficits in an animal model of amnesia. J. Pharmacol. Sci. 95, 145-152
47. Petkov, V. D., Belcheva, S., and Petkov, V. V. (2003) Behavioral effects of ginkgo biloba L., panax ginseng C.A. Mey., and gincosan. Am. J. Chin. Med. 31, 841-855
48. Dergal, J. M., Gold, J. L., Laxer, D. A., Lee, M. S., Binns, M. A., Lanctot, K. L., Freedman, M., and Rochon, P. A. (2002) Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging 19, 879-886
49. Gold, J. L., Laxer, D. A., Dergal, J. M., Lanctot, K. L., and Rochon, P. A. (2001) Herbal-drug therapy interactions: a focus on dementia. Curr. Opin. Clin. Nutr. Metab. Care 4, 29-34